{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T04:49:09Z","timestamp":1693457349189},"posted":{"date-parts":[[2023,8,7]]},"group-title":"In Review","reference-count":26,"publisher":"Research Square Platform LLC","license":[{"start":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T00:00:00Z","timestamp":1691366400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,7,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n        <jats:p>High-dose chemotherapy (HDT) followed by autologous hematopoietic stem cell transplantation (ASCT), recommended as consolidation therapy for high-risk lymphoma, or salvage therapy for relapsed\/refractory lymphoma, has shown survival benefits for patients [1-3]. However, the complications of transplant-related infection and bleeding as well as disease recurrence and progression, remain serious clinical problems to be solved.\nThe median time to platelet engraftment after ASCT ranges from 9 to 38 days [4]. Prolonged platelet engraftment increases the risk of bleeding events, even life-threatening, and also leads to platelet transfusion dependence or resistance accompanied by the increasing incidence of transfusion side effects [5]. All of the above results in prolonged hospital stay, increased medical cost and decreased quality of life for patients [6-8]. However, there is no effective therapeutic strategy to promote platelet engraftment after ASCT.\nThrombopoietin (TPO), as a hematopoietic growth factor, could promote thrombopoiesis by stimulating the differentiation of hematopoietic stem cells into megakaryocytes and the proliferation and maturation of megakaryocytes [9-12]. Recombinant human TPO (rhTPO), which retains the amino acid sequence identical to endogenous TPO, has been widely used in chemotherapy-induced thrombocytopenia, immune thrombocytopenia [13, 14] and aplastic anemia (AA) [15]. The safety of rhTPO has been established for decades in previous studies [16, 17] for decades. Recent studies in allogeneic hematopoietic stem cell transplantation (allo-HSCT) demonstrated that rhTPO could promote platelet engraftment and reduce platelet transfusion [18, 19], and even significantly improve the prognosis of patients with myelodysplastic syndrome (MDS) and AA [20]. And rhTPO was also found to accelerate platelet engraftment after ASCT in patients with multiple myeloma, especially for those with poor CD34<jats:sup>+<\/jats:sup> cell counts [21]. Our present study evaluated the efficacy and safety of rhTPO after ASCT in patients with malignant lymphoma.<\/jats:p>","DOI":"10.21203\/rs.3.rs-3207039\/v1","type":"posted-content","created":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T00:09:56Z","timestamp":1691712596000},"source":"Crossref","is-referenced-by-count":0,"title":["Recombinant human thrombopoietin improves platelet engraftment after autologous hematopoietic stem cell transplantation in patients with aggressive lymphoma"],"prefix":"10.21203","author":[{"given":"Yang","family":"Xu","sequence":"first","affiliation":[{"name":"the Second Af\ufb01liated Hospital of Zhejiang University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yili","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luyao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huawei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xibin","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boxiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiawei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liansheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"8761","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11899-017-0382-1","article-title":"A review of autologous stem cell transplantation in lymphoma","volume":"12","author":"Umar Z","year":"2017","unstructured":"Umar Z, Faisal A, Akshay A, Muhammad H, Onyee C, Irbaz BR, et al. A review of autologous stem cell transplantation in lymphoma. Curr Hematol Malig Rep 2017;12:217\u201326.","journal-title":"Curr Hematol Malig Rep"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma","volume":"333","author":"Philip T","year":"1995","unstructured":"Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma. N Engl J Med 1995;333:1540\u20135.","journal-title":"N Engl J Med"},{"key":"ref3","author":"Shipp MA","year":"1999","unstructured":"Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M, et al. International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-hodgkin\u2019s lymphoma: report of the jury. J Clin Oncol 1999;17:423-9."},{"key":"ref4","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1089\/scd.1.1996.5.407","article-title":"Thrombocytopenia after high-dose chemotherapy and autologous stem cell transplantation: an unresolved problem and possible approaches to resolve it","volume":"5","author":"Hassan HT","year":"1996","unstructured":"Hassan HT, Zander AR. Thrombocytopenia after high-dose chemotherapy and autologous stem cell transplantation: an unresolved problem and possible approaches to resolve it. J Hematother 1996;5:407\u201314.","journal-title":"J Hematother"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(12)60983-0","article-title":"Platelets-to transfuse or not to transfuse","volume":"380","author":"Neil B","year":"2012","unstructured":"Neil B, Joanna MH, Gordon LP, Richard PP. Platelets-to transfuse or not to transfuse. Lancet 2012;380:1287\u20139.","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.bbmt.2018.01.032","article-title":"Low CD34 + cell doses are associated with increased cost and worse outcome after tandem autologous stem cell transplantation in patients with relapsed or refractory germ cell tumors","volume":"24","author":"Hyder MA","year":"2018","unstructured":"Hyder MA, Goebel WS, Ervin KD, Schwartz JE, Robertson MJ, Thakrar TC, et al. Low CD34 + cell doses are associated with increased cost and worse outcome after tandem autologous stem cell transplantation in patients with relapsed or refractory germ cell tumors. Biol Blood Marrow Transplant 2018;24:1497\u2013504.","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1016\/S0959-8049(00)00327-0","article-title":"Effect of cell determinant (CD)34 + cell dose on the cost and consequences of peripheral blood stem cell transplantation for non-Hodgkin\u2019s lymphoma patients in front-line therapy","volume":"36","author":"Limat S","year":"2000","unstructured":"Limat S, Woronoff-Lemsi MC, Milpied N, Chartrin I, Ifrah N, Deconinck E, et al. Effect of cell determinant (CD)34 + cell dose on the cost and consequences of peripheral blood stem cell transplantation for non-Hodgkin\u2019s lymphoma patients in front-line therapy. Eur J Cancer 2000;36:2360\u20137.","journal-title":"Eur J Cancer"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/sj.bmt.1705818","article-title":"Failure to achieve a threshold dose of CD34 + CD110 + progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation","volume":"40","author":"Sartor MM","year":"2007","unstructured":"Sartor MM, Garvin F, Antonenas V, Bradstock KF, Gottlieb DJ. Failure to achieve a threshold dose of CD34 + CD110 + progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation. Bone Marrow Transplant 2007;40:851\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1084\/jem.183.2.651","article-title":"Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin","volume":"183","author":"Sauvage FJ","year":"1996","unstructured":"de Sauvage FJ, Carver-Moore K, Luoh SM, Ryan A, Dowd M, Eaton DL, et al. Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J Exp Med 1996; 183:651\u20136.","journal-title":"J Exp Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood.V87.6.2162.bloodjournal8762162","article-title":"Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl","volume":"87","author":"Alexander WS","year":"1996","unstructured":"Alexander WS, Roberts AW, Nicola NA, Li R, Metcalf D. Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl. Blood 1996;87:2162\u201370.","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/369568a0","article-title":"Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin","volume":"369","author":"Kaushansky K","year":"1994","unstructured":"Kaushansky K, Lok S, Holly RD, Broudy VC, Lin N, Bailey MC, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 1994;369:568\u201371.","journal-title":"Nature"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood.V86.2.419.bloodjournal862419","article-title":"Thrombopoietin: the primary regulator of platelet production","volume":"86","author":"Kaushansky K","year":"1995","unstructured":"Kaushansky K. Thrombopoietin: the primary regulator of platelet production. Blood 1995;86:419\u201331.","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1182\/blood-2014-06-581868","article-title":"A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP","volume":"125","author":"Zhou H","year":"2015","unstructured":"Zhou H, Xu M, Qin P, Zhang H-Y, Yuan C-L, Zhao H-G, et al. A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP. Blood 2015;125:1541\u20137.","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1182\/blood-2017-01-761262","article-title":"A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy","volume":"130","author":"Kong Z","year":"2017","unstructured":"Kong Z, Qin P, Xiao S, Zhou H, Li H, Yang R, et al. A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy. Blood 2017;130:1097\u2013103.","journal-title":"Blood"},{"key":"ref15","first-page":"597293","article-title":"Recombinant human thrombopoietin treatment promotes hematopoiesis recovery in patients with severe aplastic anemia receiving immunosuppressive therapy","volume":"2015","author":"Wang H","year":"2015","unstructured":"Wang H, Dong Q, Fu R, Qu W, Ruan E, Wang G, et al. Recombinant human thrombopoietin treatment promotes hematopoiesis recovery in patients with severe aplastic anemia receiving immunosuppressive therapy. Biomed Res Int 2015;2015:597293.","journal-title":"Biomed Res Int"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1083-8791(00)70049-8","article-title":"A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation","volume":"6","author":"Nash RA","year":"2000","unstructured":"Nash RA, Kurzrock R, DiPersio J, Vose J, Linker C, Maharaj D, et al. A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2000;6:25\u201334.","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"364","DOI":"10.7326\/0003-4819-132-5-200003070-00005","article-title":"Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer","volume":"132","author":"Vadhan-Raj S","year":"2000","unstructured":"Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, Broxmeyer HE, Kudelka AP, Freedman RS, et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med 2000;132:364\u20138.","journal-title":"Ann Intern Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00277-014-2158-1","article-title":"Recombinant human thrombopoietin promotes platelet engraftment after haploidentical hematopoietic stem cell transplantation: a prospective randomized controlled trial","volume":"94","author":"Han TT","year":"2015","unstructured":"Han TT, Xu LP, Liu DH, Liu KY, Wang FR, Wang Y, et al. Recombinant human thrombopoietin promotes platelet engraftment after haploidentical hematopoietic stem cell transplantation: a prospective randomized controlled trial. Ann Hematol 2015;94:117\u201328.","journal-title":"Ann Hematol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1080\/09537104.2018.1557613","article-title":"A novel recombinant human thrombopoietin for treating prolonged isolated thrombocytopenia after allogeneic stem cell transplantation","volume":"30","author":"Sun YQ","year":"2019","unstructured":"Sun YQ, Kong Y, Zhang XH, Wang Y, Shi MM, Song Y, et al. A novel recombinant human thrombopoietin for treating prolonged isolated thrombocytopenia after allogeneic stem cell transplantation. Platelets 2019;30:994\u20131000.","journal-title":"Platelets"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.bbmt.2017.06.010","article-title":"Recombinant Human Thrombopoietin Promotes Platelet Engraftment and Improves Prognosis of Patients with Myelodysplastic Syndromes and Aplastic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation","volume":"23","author":"Wang H","year":"2017","unstructured":"Wang H, Huang M, Zhao Y, Qi JQ, Chen C, Tang YQ, et al. Recombinant Human Thrombopoietin Promotes Platelet Engraftment and Improves Prognosis of Patients with Myelodysplastic Syndromes and Aplastic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2017;23:1678\u201384.","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"7641","DOI":"10.1002\/cam4.4294","article-title":"Recombinant human thrombopoietin improved platelet engraftment after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma","volume":"10","author":"Gu JL","year":"2021","unstructured":"Gu JL, Liu JR, Li XZ, Zou WY, Huang BH, Chen ML, et al. Recombinant human thrombopoietin improved platelet engraftment after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Cancer Med 2021;10:7641\u20139.","journal-title":"Cancer Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror ML","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005;106:2912\u20139.","journal-title":"Blood"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11899-017-0382-1","article-title":"A review of autologous stem cell transplantation in lymphoma","volume":"12","author":"Zahid U","year":"2017","unstructured":"Zahid U, Akbar F, Amaraneni A, Husnain M, Chan O, Riaz IB, et al. A review of autologous stem cell transplantation in lymphoma. Curr Hematol Malig Req 2017;12:217\u201326.","journal-title":"Curr Hematol Malig Req"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/j.bbmt.2014.08.019","article-title":"Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma","volume":"20","author":"Dahi PB","year":"2014","unstructured":"Dahi PB, Tamari R, Devlin SM, Maloy M, Bhatt V, Scordo M, et al. Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma. Bio Blood Marrow Transplant 2014;20:2004\u20139.","journal-title":"Bio Blood Marrow Transplant"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12885-016-2311-4","article-title":"High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma \u2013 a randomized phase III trial (MATRix)","volume":"16","author":"Schorb E","year":"2016","unstructured":"Schorb E, Finke J, Ferreri AJ, Ihorst G, Mikesch K, Kasenda B, et al. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma \u2013 a randomized phase III trial (MATRix). BMC Cancer 2016;16:282.","journal-title":"BMC Cancer"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/sj.bmt.1702772","article-title":"Recombinant human thrombopoietin (rhTPO) after autologous bone marrow transplantation: a phase I pharmacokinetic and pharmacodynamic study","volume":"27","author":"Wolff SN","year":"2001","unstructured":"Wolff SN, Herzig R, Lynch J, Ericson SG, Greer JP, Stein R, et al. Recombinant human thrombopoietin (rhTPO) after autologous bone marrow transplantation: a phase I pharmacokinetic and pharmacodynamic study. Bone Marrow Transplantation 2001;27:261\u20138.","journal-title":"Bone Marrow Transplantation"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3207039\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3207039\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T11:26:06Z","timestamp":1693394766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3207039\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,7]]},"references-count":26,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-3207039\/v1","relation":{},"subject":[],"published":{"date-parts":[[2023,8,7]]},"subtype":"preprint"}}